A detailed history of Janus Henderson Group PLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 115,273 shares of AKBA stock, worth $195,964. This represents 0.0% of its overall portfolio holdings.

Number of Shares
115,273
Holding current value
$195,964
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$2.7 - $4.01 $311,237 - $462,244
115,273 New
115,273 $311,000
Q2 2022

Aug 15, 2022

SELL
$0.32 - $0.67 $9,530 - $19,955
-29,784 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$0.72 - $2.93 $6 - $26
9 Added 0.03%
29,784 $22,000
Q4 2021

Feb 14, 2022

BUY
$2.26 - $3.34 $33,967 - $50,200
15,030 Added 101.93%
29,775 $67,000
Q3 2021

Nov 16, 2021

BUY
$2.35 - $3.88 $34,650 - $57,210
14,745 New
14,745 $42,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $313M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.